Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by canadapieton Nov 28, 2019 6:44pm
149 Views
Post# 30403915

RE:RE:RE:Bucknely

RE:RE:RE:BucknelyMister Wino,

thanks !!!

Like i said before, i am a long term investor who is looking at the 
fundamentals of a company! Mostly i am in it for a long time and anybody 
can see how long that is(was) with Th!!!
What i don't understand (but actually  i do......) is that we (here on the MB )
search for reasons why some things happen, and what maybe the future can
bring for the company, but The Management, our BOD (ceo, cfo, cmo etc)
can't give a "directive" .
I sold because of that! + the fact i thought an other investment would
generate more money (and it did, GLPG you now.........) !!! 

Look,i am an investor for over 30 years and i began with
a Canadian company " Biochem pharma". In the beginning a fiasco
(went from 11 to 1,50 cad .........but then.........kaboum!!!) .
Most of the people invest for 1 reason, i do it for 2.......!!
But you must make a gain(reason 1...), otherwise.......
So what my concerne is with Th is that they are not open with us. It is as if
they don't have a concrete plan and let the things come by as they come......,
Nash/Nafld is falling suddenly out of the sky!  
There is an enormous potential here, but only if they execute !!! And till now 
it was not a wonderfull performance........

I really hope the best for you all, it is a great MB!!!! We can learn  a lot from 
each other, lets keep it polite and intresting/intruiging.....

Ps: i bought some back at 4,15/4,20
Ps2: buy GLPG ( and thank me later)  

Wino115 - (11/28/2019 5:26:21 PM) 
RE:RE:Bucknely

Canadapiet has been bearish and has contributed his point of view on why.  He's also been realistic in saying if certain things happen and at certain prices, he may see another opportunity.  That kind of stuff is helpful and respectful.  Make your contributions count instead of just ranting or name-calling.  It takes a lot more work to do that as opposed to silly posts filled with insults.  Those are easy to do, but community-minded participants prefer not to do that.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities